1,2,6-substituted benzimidazoles as flap modulators

A compound of Formula (I)

• wherein:
• X1 is H Cl, or F;
• X1′ is H, Cl, or F;
• X1″ is H, or F;
• R1 is
• X2 is H, F, or Cl;
• R2 is
• Rx is Br, CH3, —CN,
• X3 is H, or F;
• X4 is H, or F;
• X5 is H, Br, Cl, CH3, OCH3, or F;
• X6 is H, Cl, CH3, or F;
• X7 is H, F, CH3, or C(CH3)3;
• and
• R3 is
• provided that the second eluting isomer of racemic cis-2-{1-(4-Cyanobenzyl)-6-[(5-methylpyridin-2-yl)methoxy]-1H-benzimidazol-2-yl}cyclohexanecarboxylic acid when purified by chiral SFC on (CHIRALCEL OJ-H 5 μm 250×20 mm) mobile phase (65% CO2, 35% EtOH), the second eluting isomer of racemic cis-3-{1-(4-Bromo-2-fluorobenzyl)-6-[(5-methylpyridin-2-yl)methoxy]-1H-benzimidazol-2-yl}-2,2-dimethylcyclopropanecarboxylic acid when purified by chiral SFC on (CHIRALPAK AD-H 5 μm 250×20 mm) mobile phase (60% CO2, 40% MeOH), and the first eluting isomer of racemic cis-2-{1-[2-Fluoro-4-(trifluoromethoxy)benzyl]-6-[(1-methyl-1H-pyrazol-3-yl)methoxy]-1H-benzimidazol-2-yl}cyclohexanecarboxylic acid when purified by chiral SFC(CHIRALCEL OD-H 5 μm 250×20 mm) mobile phase (80% CO2, 20% MeOH) are specifically disclaimed;
• and solvates, hydrates, and pharmaceutically acceptable salts thereof.